ASX - By Stock
|
RAC |
Re:
Ann: Race Oncology Share Purchase Plan Opens
|
|
Lymphnode63
|
557 |
160K |
4 |
26/11/21 |
26/11/21 |
ASX - By Stock
|
557
|
160K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Oncology Share Purchase Plan Opens
|
|
Lymphnode63
|
557 |
160K |
7 |
26/11/21 |
26/11/21 |
ASX - By Stock
|
557
|
160K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Trading Halt
|
|
Lymphnode63
|
218 |
66K |
0 |
23/11/21 |
23/11/21 |
ASX - By Stock
|
218
|
66K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Breakthrough Zantrene Heart Protection Discovery
|
|
Lymphnode63
|
366 |
122K |
10 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
366
|
122K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Breakthrough Zantrene Heart Protection Discovery
|
|
Lymphnode63
|
366 |
122K |
1 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
366
|
122K
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano Placement and Entitlement Offer
|
|
Lymphnode63
|
142 |
53K |
0 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
142
|
53K
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano Placement and Entitlement Offer
|
|
Lymphnode63
|
142 |
53K |
1 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
142
|
53K
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano Placement and Entitlement Offer
|
|
Lymphnode63
|
142 |
53K |
1 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
142
|
53K
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano Placement and Entitlement Offer
|
|
Lymphnode63
|
142 |
53K |
0 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
142
|
53K
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano Placement and Entitlement Offer
|
|
Lymphnode63
|
142 |
53K |
3 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
142
|
53K
|
3
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano Placement and Entitlement Offer
|
|
Lymphnode63
|
142 |
53K |
1 |
11/11/21 |
11/11/21 |
ASX - By Stock
|
142
|
53K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Ann: University of Wollongong R&D Collaboration
|
|
Lymphnode63
|
167 |
41K |
16 |
09/11/21 |
09/11/21 |
ASX - By Stock
|
167
|
41K
|
16
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Trading halt
|
|
Lymphnode63
|
185 |
75K |
0 |
09/11/21 |
09/11/21 |
ASX - By Stock
|
185
|
75K
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Trading halt
|
|
Lymphnode63
|
185 |
75K |
1 |
08/11/21 |
08/11/21 |
ASX - By Stock
|
185
|
75K
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Trading halt
|
|
Lymphnode63
|
185 |
75K |
0 |
08/11/21 |
08/11/21 |
ASX - By Stock
|
185
|
75K
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Trading halt
|
|
Lymphnode63
|
185 |
75K |
5 |
08/11/21 |
08/11/21 |
ASX - By Stock
|
185
|
75K
|
5
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Trading halt
|
|
Lymphnode63
|
185 |
75K |
0 |
08/11/21 |
08/11/21 |
ASX - By Stock
|
185
|
75K
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Trading halt
|
|
Lymphnode63
|
185 |
75K |
4 |
08/11/21 |
08/11/21 |
ASX - By Stock
|
185
|
75K
|
4
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: Ceasing to be a substantial holder
|
|
Lymphnode63
|
13 |
5.4K |
0 |
03/11/21 |
03/11/21 |
ASX - By Stock
|
13
|
5.4K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Zantrene highly effective in Melanoma preclinical study
|
|
Lymphnode63
|
179 |
62K |
7 |
30/09/21 |
30/09/21 |
ASX - By Stock
|
179
|
62K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Zantrene highly effective in Melanoma preclinical study
|
|
Lymphnode63
|
179 |
62K |
6 |
30/09/21 |
30/09/21 |
ASX - By Stock
|
179
|
62K
|
6
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Lymphnode63
|
11K |
3.8M |
6 |
23/09/21 |
23/09/21 |
General
|
11K
|
3.8M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Lymphnode63
|
17K |
6.8M |
0 |
16/09/21 |
16/09/21 |
ASX - By Stock
|
17K
|
6.8M
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Voluntary suspension
|
|
Lymphnode63
|
194 |
93K |
1 |
02/09/21 |
02/09/21 |
ASX - By Stock
|
194
|
93K
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Voluntary suspension
|
|
Lymphnode63
|
194 |
93K |
8 |
01/09/21 |
01/09/21 |
ASX - By Stock
|
194
|
93K
|
8
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Voluntary suspension
|
|
Lymphnode63
|
194 |
93K |
2 |
01/09/21 |
01/09/21 |
ASX - By Stock
|
194
|
93K
|
2
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Voluntary suspension
|
|
Lymphnode63
|
194 |
93K |
1 |
01/09/21 |
01/09/21 |
ASX - By Stock
|
194
|
93K
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Commercial Partnership[!!
|
|
Lymphnode63
|
484 |
245K |
1 |
01/09/21 |
01/09/21 |
ASX - By Stock
|
484
|
245K
|
1
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Pause in trading
|
|
Lymphnode63
|
120 |
52K |
2 |
01/09/21 |
01/09/21 |
ASX - By Stock
|
120
|
52K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Annual Financial Results and Operational Progress
|
|
Lymphnode63
|
206 |
62K |
3 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
206
|
62K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Speculative M&A Transaction Analysis
|
|
Lymphnode63
|
740 |
275K |
5 |
27/08/21 |
27/08/21 |
ASX - By Stock
|
740
|
275K
|
5
|
|
ASX - By Stock
|
RAC |
Re:
Speculative M&A Transaction Analysis
|
|
Lymphnode63
|
740 |
275K |
9 |
27/08/21 |
27/08/21 |
ASX - By Stock
|
740
|
275K
|
9
|
|
ASX - By Stock
|
RAC |
Re:
Speculative M&A Transaction Analysis
|
|
Lymphnode63
|
740 |
275K |
2 |
27/08/21 |
27/08/21 |
ASX - By Stock
|
740
|
275K
|
2
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Lymphnode63
|
11K |
3.8M |
18 |
25/08/21 |
25/08/21 |
General
|
11K
|
3.8M
|
18
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Lymphnode63
|
11K |
3.8M |
6 |
25/08/21 |
25/08/21 |
General
|
11K
|
3.8M
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Speculative M&A Transaction Analysis
|
|
Lymphnode63
|
740 |
275K |
11 |
20/08/21 |
20/08/21 |
ASX - By Stock
|
740
|
275K
|
11
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Lymphnode63
|
11K |
3.8M |
2 |
13/08/21 |
13/08/21 |
General
|
11K
|
3.8M
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: First Patient Dosed in Phase 1b/2 AML Trial
|
|
Lymphnode63
|
245 |
84K |
10 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
245
|
84K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Ann: First Patient Dosed in Phase 1b/2 AML Trial
|
|
Lymphnode63
|
245 |
84K |
2 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
245
|
84K
|
2
|
|
ASX - By Stock
|
LKE |
Re:
Ann: LKE Bonus Issue to Shareholders
|
|
Lymphnode63
|
389 |
135K |
3 |
03/08/21 |
03/08/21 |
ASX - By Stock
|
389
|
135K
|
3
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: Appendix 4C & Quarterly Activities Report
|
|
Lymphnode63
|
48 |
16K |
1 |
30/07/21 |
30/07/21 |
ASX - By Stock
|
48
|
16K
|
1
|
|
ASX - By Stock
|
PBH |
Re:
Media Update
|
|
Lymphnode63
|
1.4K |
582K |
0 |
30/07/21 |
30/07/21 |
ASX - By Stock
|
1.4K
|
582K
|
0
|
|
ASX - By Stock
|
PBH |
Re:
Media Update
|
|
Lymphnode63
|
1.4K |
582K |
0 |
30/07/21 |
30/07/21 |
ASX - By Stock
|
1.4K
|
582K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
Lymphnode63
|
127 |
41K |
8 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
127
|
41K
|
8
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Lymphnode63
|
11K |
3.8M |
7 |
28/07/21 |
28/07/21 |
General
|
11K
|
3.8M
|
7
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Lymphnode63
|
11K |
3.8M |
4 |
28/07/21 |
28/07/21 |
General
|
11K
|
3.8M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Another AFR Article - this time on the Angioblast deal
|
|
Lymphnode63
|
98 |
24K |
0 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
98
|
24K
|
0
|
|
ASX - By Stock
|
WBT |
Re:
Ann: Weebit Nano Q4 FY21 Activities Report and Appendix 4C
|
|
Lymphnode63
|
184 |
76K |
3 |
23/07/21 |
23/07/21 |
ASX - By Stock
|
184
|
76K
|
3
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
Lymphnode63
|
11K |
3.8M |
2 |
21/07/21 |
21/07/21 |
General
|
11K
|
3.8M
|
2
|
|
ASX - By Stock
|
WBT |
Re:
Ann: WBT completes design and tape-out of embedded ReRAM module
|
|
Lymphnode63
|
80 |
37K |
1 |
14/07/21 |
14/07/21 |
ASX - By Stock
|
80
|
37K
|
1
|
|